SecBot SecBot
Biotech Drug Report Generated Oct 26, 2026

EQ504

EQ·Equillium, Inc.
NEUTRAL
Drug Impact Rating5/10
Trial phase
Phase 1
Time to market
Unknown, the drug is in Phase 1 healthy-volunteer testing. If successful through Phase 2 and Phase 3, potential approval would be several years away (likely 2029-2031 at the earliest).
Why 5/10
The next hard catalyst is Phase 1 topline proof-of-mechanism data anticipated in Q2 2027 (~6 months from now). This is not a pivotal readout or PDUFA, it is an early safety/PK/PD study in healthy volunteers, so it does not qualify for the 6-7 tier reserved for binary pivotal events. However, EQ504 is now Equillium's lead value driver after itolizumab's Phase 3 failure, and the company has no approved products or revenue, so the data readout is material. Score 5 reflects a mid-stage (Phase 1) asset that is the company's primary focus with a catalyst within ~6 months.
Actionable Insight NEUTRAL

The next hard catalyst is topline Phase 1 proof-of-mechanism data in Q2 2027 (~6 months from now). Positive data showing AhR target engagement and a clean safety profile in healthy volunteers would validate the mechanism and support advancement into a Phase 2 proof-of-concept study in ulcerative colitis patients in H2 2027. Negative safety signals or failure to demonstrate target engagement would severely damage the thesis for a company now entirely dependent on EQ504 after its prior lead failed Phase 3.

Price Chart

Loading chart...

Executive Summary

EQ504 is Equillium's oral, colon-targeted aryl hydrocarbon receptor (AhR) modulator in Phase 1 development for ulcerative colitis and potentially other inflammatory diseases. The company dosed the first healthy volunteer on October 26, 2026, triggering a $20M milestone tranche under its August 2025 financing. Topline proof-of-mechanism data is expected in Q2 2027. EQ504 is now Equillium's lead asset after its prior drug itolizumab (EQ001) missed its Phase 3 primary endpoint in acute GVHD and failed to secure FDA breakthrough designation. The company has ~$57M cash (as of June 30, 2026) plus the new $20M, funding operations into 2029. Analyst consensus is Strong Buy with a mean price target of $8.56, but the stock trades near $1.12, reflecting the binary risk of an early-stage, single-asset biotech with no approved products and no revenue.

How It Works

EQ504 is an oral pill designed to activate the aryl hydrocarbon receptor (AhR), a protein that acts like a master switch in the gut to calm inflammation, repair the intestinal lining, and promote immune tolerance, without broadly suppressing the immune system. It is formulated with an enteric coating to release the drug directly in the colon, targeting the site of disease in ulcerative colitis.

Trial Status

The Phase 1 first-in-human trial (NCT07869225) is a randomized, double-blind, placebo-controlled study in approximately 70 healthy volunteers in Australia. It includes single ascending dose (SAD), multiple ascending dose (MAD), and an optional food-effect cohort, testing once-daily oral doses from 0.1 to 3.0 mg. The first subject was dosed on October 26, 2026. Topline proof-of-mechanism data is expected in Q2 2027. A Phase 2 proof-of-concept study in ulcerative colitis patients is planned for the second half of 2027, contingent on Phase 1 results.

The Two-Sided Case

▲ Bull Case4
EQ504 targets a clinically validated pathway (AhR), the same mechanism behind indigo naturalis and VTAMA (tapinarof) in inflammatory diseases, with a novel, non-immunosuppressive approach that could differentiate it from existing UC therapies like JAK inhibitors and biologics.
The company has a strong cash runway into 2029 (~$57M as of June 30, 2026, plus a $20M milestone triggered by the first dosing), reducing near-term dilution risk and funding through multiple data readouts.
Analyst consensus is Strong Buy with a mean price target of $8.56 (595.6% implied upside from the current ~$1.12 price), reflecting optimism about the AhR mechanism and the large UC market (>$15B projected).
The colon-targeted enteric-coated oral formulation could offer a convenient, locally acting treatment option for UC patients, potentially with fewer systemic side effects than current standard-of-care therapies.
▼ Bear Case5
EQ504 is a Phase 1 asset with zero clinical data in humans, the entire thesis rests on preclinical models and a mechanism that has yet to show efficacy in UC clinical trials.
Equillium's prior lead asset, itolizumab (EQ001), failed its Phase 3 EQUATOR study in acute GVHD (missed primary endpoint) and was rejected by the FDA for breakthrough designation, raising questions about management's drug development track record.
The stock trades near $1.12 with ~8.74% of shares sold short (as of Sep 30, 2026), reflecting skepticism about the company's ability to deliver value from an early-stage pipeline.
The UC treatment market is crowded with approved biologics (Humira, Entyvio, Stelara), JAK inhibitors (Xeljanz, Rinvoq), and S1P receptor modulators (Zeposia), making it difficult for a Phase 1 oral drug to carve out commercial share even if technically successful.
Several institutional investors trimmed or exited positions in Q2 2026, including Adage Capital (-73.9% trim), Balyasny (-79%), and Susquehanna (-81.6%), suggesting mixed conviction among sophisticated holders.

Upcoming Catalysts

  • Phase 1 topline proof-of-mechanism data expected Q2 2027
  • Potential Phase 2 proof-of-concept study initiation in ulcerative colitis patients in H2 2027 (contingent on Phase 1 results)
  • Q3 2026 earnings report on November 11, 2026

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Equillium, Inc. Press Release EQ ·Originating report

Sources · 9

Hover a chip for the title
1 equilliumbio.com2 tmcnet.com3 equilliumbio.com4 businesswire.com5 equilliumbio.com6 equilliumbio.com7 marketbeat.com8 streetinsider.com9 clinicaltrials.gov